Oncology

Live Report from ASH:
Interleukin-2 For Acute Myeloid Leukemia In First Remission?

December 10, 2007

AudioMedica News

00:00 /

Jonathan Kolitz

JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY
GEORGE CANELLOS, Dana-Farber Cancer Institute
For patients with acute myeloid leukemia in first remission, new data suggests that there may be a benefit from interleukin-2. Derek Thorne got the interim results of this phase III trial from Jonathan Kolitz of Monter Cancer Center, Lake Success, NY, while George Canellos of the Dana-Farber Cancer Institute provided comment.

[audio:https://www.audiomedica.com/podcasting/oncology/071209_jonathan_kolitz.mp3]

Tagged as:acute cancer leukemia myeloid News patient podcast podcasting report reports trial

AUDIO JOURNAL OF ONCOLOGY—Progression to Acute Myeloid Leukemia Explained by Multi Omics Analysis

October 9, 2022

A new research method has elucidated cellular processes (involving mutated TP53 oncogene) that can convert a relatively benign myeloproliferative...

Infectious Disease AJO Cardiovascular General Medicine News Oncology Primary Health Care Public Health Video

COVID-19 Co-Morbidity Risks Quantified from Three Continents Survey

May 28, 2020

Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...

Audio AJO Oncology

CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second Study Confirms

February 24, 2020

Audio Journal of Oncology Podcast CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second Study Confirms Play Episode Pause Episode Mute/Unmute...

Audio AJO Oncology

Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per Cent

February 7, 2020

Audio Journal of Oncology Podcast Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per Cent Play Episode Pause Episode Mute/Unmute Episode...

Audio AJO Oncology

New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

January 24, 2020

Audio Journal of Oncology Podcast New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia Play Episode Pause Episode Mute/Unmute...

Audio AJO Oncology

Microbiome Diversity Key To Survival After Allogeneic Hematopoietic Cell Transplantation

January 14, 2020

Audio Journal of Oncology Podcast Microbiome Diversity Key To Survival After Allogeneic Hematopoietic Cell Transplantation Play Episode Pause Episode...

Live Report from ASH:
Interleukin-2 For Acute Myeloid Leukemia In First Remission?

Further reading

AUDIO JOURNAL OF ONCOLOGY—Progression to Acute Myeloid Leukemia Explained by Multi Omics Analysis

COVID-19 Co-Morbidity Risks Quantified from Three Continents Survey

CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second Study Confirms

Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per Cent

New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

Microbiome Diversity Key To Survival After Allogeneic Hematopoietic Cell Transplantation

Menu

Live Report from ASH:Interleukin-2 For Acute Myeloid Leukemia In First Remission?

Further reading

AUDIO JOURNAL OF ONCOLOGY—Progression to Acute Myeloid Leukemia Explained by Multi Omics Analysis

COVID-19 Co-Morbidity Risks Quantified from Three Continents Survey

CT Screening Cuts Lung Cancer Deaths 24 Per Cent—Second Study Confirms

Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per Cent

New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

Microbiome Diversity Key To Survival After Allogeneic Hematopoietic Cell Transplantation

Menu

Live Report from ASH:
Interleukin-2 For Acute Myeloid Leukemia In First Remission?